title: [Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia].
abstract: BACKGROUND
  Pathological myopia is one of the leading causes of vision loss worldwide, especially among young people of working age. Choroidal neovascularization is one of the most important cause of visual impairment in pathological myopia.
  
  
  OBJECTIVE
  To evaluate the efficacy of intravitreal ranibizumab for the treatment of myopic choroidal neovascularization.
  
  
  METHODS
  In this retrospective analysis 14 eyes of 14 patients (mean age: 61 ± 17 years) with myopic choroidal neovascularization were treated with intravitreal ranibizumab as needed. Best-corrected visual acuity, thickness of choroidal neovascularization lesion and the number of injections were assessed.
  
  
  RESULTS
  The mean visual acuity changed from 55.8 ± 19.3 letters to 64.8 + 15.5 at 12 months (p = 0.0414), and 62.6 ± 16.3 during follow-up time (p = 0.2896). Mean follow-up time was 19.7 ± 23.9 months, average number of injections was 2.8 ± 2.1. Visual acuity declined in four patients despite the treatment.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab is an effective therapy in pathological myopia. Some patients experience deterioration of visual acuity despite of treatment. Orv. Hetil., 2017, 158(15), 579-586.
authors.affiliation: Pest Megyei Flór Ferenc Kórház Kistarcsa, Semmelweis tér 1., 2143.
authors.forename: Regina
authors.initials: R
authors.lastname: Lukács
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: Gábor
authors.initials: G
authors.lastname: Sándor
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: Miklós
authors.initials: M
authors.lastname: Resch
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: Antal
authors.initials: A
authors.lastname: Szabó
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: György
authors.initials: G
authors.lastname: Barcsay
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: Mónika
authors.initials: M
authors.lastname: Ecsedy
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Szepessy
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: Zoltán Zsolt
authors.initials: ZZ
authors.lastname: Nagy
authors.affiliation: Szemészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
authors.forename: András
authors.initials: A
authors.lastname: Papp
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized
keywords: chorioidea-neovascularisatio; choroidal neovascularization; intravitreal injection; intravitrealis injekció; pathological myopia; patológiás myopia; ranibizumab